NASDAQ:AGEN

Agenus Stock Forecast, Price & News

$5.26
-0.06 (-1.13 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.18
$5.38
50-Day Range
$2.56
$5.32
52-Week Range
$2.50
$5.95
Volume6.91 million shs
Average Volume4.48 million shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.37
30 days | 90 days | 365 days | Advanced Chart
Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.


Agenus logo

About Agenus

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.43 out of 5 stars

Medical Sector

687th out of 2,097 stocks

Biological Products, Except Diagnostic Industry

98th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Agenus (NASDAQ:AGEN) Frequently Asked Questions

Is Agenus a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Agenus stock.
View analyst ratings for Agenus
or view top-rated stocks.

What stocks does MarketBeat like better than Agenus?

Wall Street analysts have given Agenus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Agenus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Agenus
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) issued its quarterly earnings data on Wednesday, May, 5th. The biotechnology company reported ($0.27) EPS for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.04. The biotechnology company had revenue of $11.72 million for the quarter, compared to the consensus estimate of $21.81 million.
View Agenus' earnings history
.

How has Agenus' stock price been impacted by COVID-19?

Agenus' stock was trading at $2.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGEN stock has increased by 93.4% and is now trading at $5.26.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AGEN?

3 equities research analysts have issued 12 month target prices for Agenus' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Agenus' stock price to reach $8.00 in the next year. This suggests a possible upside of 52.1% from the stock's current price.
View analysts' price targets for Agenus
or view top-rated stocks among Wall Street analysts.

Who are Agenus' key executives?

Agenus' management team includes the following people:
  • Garo H. Armen, Chairman & Chief Executive Officer
  • Jennifer S Buell, President & Chief Operating Officer
  • Christine M. Klaskin, Chief Financial & Accounting Officer, VP-Finance
  • Marc van Dijk, Chief Technology Officer
  • Steven O’Day, Chief Medical Officer

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus CEO Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among Agenus' employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Agenus' key competitors?

What other stocks do shareholders of Agenus own?

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.41%), RTW Investments LP (6.19%), Oracle Investment Management Inc. (4.21%), Cormorant Asset Management LP (3.48%), Millennium Management LLC (1.84%) and Geode Capital Management LLC (1.26%).
View institutional ownership trends for Agenus
.

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Morgan Stanley, Millennium Management LLC, Ikarian Capital LLC, BlackRock Inc., Credit Suisse AG, Verition Fund Management LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Agenus
or view top insider-selling stocks.

Which institutional investors are buying Agenus stock?

AGEN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., RTW Investments LP, Citigroup Inc., Cormorant Asset Management LP, Rafferty Asset Management LLC, Nuveen Asset Management LLC, Geode Capital Management LLC, and UBS Group AG.
View insider buying and selling activity for Agenus
or or view top insider-buying stocks.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $5.26.

How much money does Agenus make?

Agenus has a market capitalization of $1.17 billion and generates $88.17 million in revenue each year. The biotechnology company earns $-180,910,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Agenus have?

Agenus employs 359 workers across the globe.

What is Agenus' official website?

The official website for Agenus is agenusbio.com.

Where are Agenus' headquarters?

Agenus is headquartered at 3 FORBES ROAD, LEXINGTON MA, 02421.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (781) 674-4400 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.